A promising investigational therapy, ENV105(aka Carotuximab, aka TRC105), is offering new hope for patients with castrate-resistant prostate cancer (CRPC) and non-small cell lung cancer. By targeting CD105 (endoglin), a key player in tumor progression and resistance, ENV105 is designed to restore sensitivity to existing treatments.

ENV105 is a monoclonal antibody that binds to CD105, a protein involved in cancer cell survival and resistance mechanisms. In prostate cancer, particularly CRPC, tumors often evade standard hormone therapies such as androgen receptor inhibitors. ENV105 disrupts the BMP/CD105 signaling pathway, which is implicated in resistance, making tumors more responsive to these treatments.

A Phase 2 trial is currently evaluating ENV105 in combination with apalutamide, an androgen receptor antagonist, in a multi-center study enrolling 100 patients who have developed resistance to androgen-targeted therapies. Early findings from a previous study reported a 62% clinical benefit rate in CRPC patients with limited treatment options. The ongoing study is assessing PSA response and radiographic tumor reduction, with interim safety data expected in early 2025.

The research on ENV105 has received backing from the National Cancer Institute (NCI) and partnerships with institutions such as Cedars-Sinai Medical Center.

The early results from ENV105 trials suggest a significant step forward in tackling cancer resistance. If successful, ENV105 could become a groundbreaking addition to treatment regimens for both prostate and lung cancer, providing new therapeutic options for patients who have exhausted standard treatments.

Clinical trial.